<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36064">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02637076</url>
  </required_header>
  <id_info>
    <org_study_id>017-2014</org_study_id>
    <nct_id>NCT02637076</nct_id>
  </id_info>
  <brief_title>Xyrem and Brain Dopamine in Narcolepsy</brief_title>
  <official_title>Does Xyrem Influence Brain Dopamine in Patients With Narcolepsy? A PET Imaging Investigation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre for Addiction and Mental Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre for Addiction and Mental Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall aim is to establish whether the drug Xyrem速 has an action on the brain dopamine
      system in patients with narcolepsy.

      Trial Objective is to establish, using positron emission tomography (PET), in Xyrem速-na誰ve
      narcolepsy with cataplexy patients, whether a single dose of Xyrem速 causes changes in
      striatal binding of 11C-raclopride and 11C-DTBZ that would suggest altered activity of brain
      dopamine neurones.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in PET 11C-raclopride binding from baseline to 7 hours post Xyrem</measure>
    <time_frame>7 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood gamma-hydroxybutyrate (GHB) concentration</measure>
    <time_frame>multiple time points from 0 to 7 hours post-Xyrem</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Narcolepsy With Cataplexy</condition>
  <arm_group>
    <arm_group_label>narcolepsy with cataplexy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients given single dose of Xyrem</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xyrem</intervention_name>
    <description>single 3.0 gram dose</description>
    <arm_group_label>narcolepsy with cataplexy</arm_group_label>
    <other_name>Sodium Oxybate</other_name>
    <other_name>gamma-hydroxybutyrate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  narcolepsy with cataplexy

        Exclusion Criteria:

          -  significant unstable or uncontrolled medical/psychiatric disease

          -  significant history of head trauma/surgery or seizure disorder

          -  radiation exposure exceeding 20mSv in last 12 months

          -  pregnancy

          -  substance abuse/dependence (including alcohol)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen J Kish, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Addiction and Mental Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tina McCluskey, M.Sc.</last_name>
    <phone>416-535-8501</phone>
    <phone_ext>36241</phone_ext>
    <email>tina.mccluskey@camh.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre for Addiction and Mental Health (CAMH)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 1R8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina McCluskey, M.Sc.</last_name>
      <phone>416-535-8501</phone>
      <phone_ext>36241</phone_ext>
      <email>tina.mccluskey@camh.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 8, 2016</lastchanged_date>
  <firstreceived_date>December 17, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre for Addiction and Mental Health</investigator_affiliation>
    <investigator_full_name>Stephen Kish</investigator_full_name>
    <investigator_title>Senior Scientist, Head Human Brain Lab</investigator_title>
  </responsible_party>
  <keyword>Xyrem</keyword>
  <keyword>narcolepsy with cataplexy</keyword>
  <keyword>positron emission tomography</keyword>
  <keyword>dopamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Narcolepsy</mesh_term>
    <mesh_term>Cataplexy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dopamine</mesh_term>
    <mesh_term>Dopamine Agents</mesh_term>
    <mesh_term>Sodium Oxybate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
